Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Cell & Cellular Life Sciences Journal Research Article 3 min read

Bad Boy with a Twist: Targeting the 37 kDa/67 kDa Laminin Receptor for Treatment of Cancer and Neurodegenerative Diseases and for Changing Telomere Dynamics

Stefan FT Weiss*
* Corresponding author
ISSN: 2578-4811  10.23880/cclsj-16000114  Received: July 18, 2017  Published: August 03, 2017
 — views
 16 references
PDF

Acknowledgement

This work is based upon research supported by the National Research Foundation (NRF), the Republic of South Africa (RSA). Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s), and therefore, the National Research Foundation does not accept any liability in this regard thereto. Financial support was further received from the South African Medical Research Council (MRC) under a self-initiated grant awarded to SFTW and under the Wits Common Epithelial Cancer Research Centre (CECRC) grant. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s), and therefore, the MRC does not accept any liability in this regard thereto.

References

  1. Jovanovic K, Chetty CJ, Khumalo T, Da Costa Dias B, Ferreira E, et al. (2015) Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease. Expert opinion on therapeutic patents 25(5): 567- 582.
  2. DiGiacomo V, Meruelo D (2016) Looking into laminin receptor: critical discussion regarding the non- integrin 37/67-kDa laminin receptor/RPSA protein. Biological reviews of the Cambridge Philosophical Society 91(2): 288-310.
  3. Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, et al. (2001) The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. The EMBO journal 20(21): 5863-5875.
  4. Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, et al. (2006) The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. The Journal of infectious diseases 194(5): 702-709.
  5. Mbazima V, Da Costa Dias B, Omar A, Jovanovic K, Weiss SF (2010) Interactions between PrP(c) and other ligands with the 37-kDa/67-kDa laminin receptor. Frontiers in bioscience 15: 1150-1163.
  6. Zuber C, Mitteregger G, Pace C, Zerr I, Kretzschmar HA, et al. (2007) Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 1(3): 207-212.
  7. Pinnock EC, Jovanovic K, Pinto MG, Ferreira E, Dias Bda C, et al. (2016) LRP/LR Antibody Mediated Rescuing of Amyloid-beta-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. Journal of Alzheimer's disease: JAD 49(3): 645-657.
  8. Rebelo TM, Chetty CJ, Ferreira E, Weiss SF (2016) Anti-LRP/LR-specific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells. BMC cancer 16: 917. Cell & Cellular Life Sciences Journal
  9. Vania L, Chetty CJ, Ferreira E, Weiss SF (2016) Anti- LRP/LR specific antibody IgG1-iS18 significantly impedes adhesion and invasion in early and late stage colorectal carcinoma cells. Molecular medicine 8: 22.
  10. Munien C, Rebelo TM, Ferreira E, Weiss SF (2017) IgG1-iS18 impedes the adhesive and invasive potential of early and late stage malignant melanoma cells. Experimental cell research 351(2): 135-141.
  11. Khusal R, Da Costa Dias B, Moodley K, Penny C, Reusch U, et al. (2013) In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PloS one 8(3): e58888.
  12. Moodley K, Weiss SF (2013) Downregulation of the non-integrin laminin receptor reduces cellular viability by inducing apoptosis in lung and cervical cancer cells. PloS one 8(3): e57409.
  13. Khumalo T, Ferreira E, Jovanovic K, Veale RB, Weiss SF (2015) Knockdown of LRP/LR Induces Apoptosis in Breast and Oesophageal Cancer Cells. PloS one 10(10): e0139584.
  14. Saretzki G (2014) Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. Current pharmaceutical design 20(41): 6386- 6403.
  15. Naidoo K, Malindisa ST, Otgaar TC, Bernert M, Da Costa Dias B, et al. (2015) Knock-Down of the 37kDa/67kDa Laminin Receptor LRP/LR Impedes Telomerase Activity. PloS one 10(11): e0141618.
  16. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, et al. (1999) Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature genetics 21(1): 115-118.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{stefan2017,
  title   = {Bad Boy with a Twist: Targeting the 37 kDa/67 kDa Laminin Receptor for Treatment of Cancer and Neurodegenerative Diseases and for Changing Telomere Dynamics},
  author  = {Stefan FT Weiss},
  journal = {Cell & Cellular Life Sciences Journal},
  year    = {2017},
  volume  = {2},
  number  = {2},
  doi     = {10.23880/cclsj-16000114}
}
Stefan FT Weiss (2017). Bad Boy with a Twist: Targeting the 37 kDa/67 kDa Laminin Receptor for Treatment of Cancer and Neurodegenerative Diseases and for Changing Telomere Dynamics. Cell & Cellular Life Sciences Journal, 2(2). https://doi.org/10.23880/cclsj-16000114
TY  - JOUR
TI  - Bad Boy with a Twist: Targeting the 37 kDa/67 kDa Laminin Receptor for Treatment of Cancer and Neurodegenerative Diseases and for Changing Telomere Dynamics
AU  - Stefan FT Weiss
JO  - Cell & Cellular Life Sciences Journal
PY  - 2017
VL  - 2
IS  - 2
DO  - 10.23880/cclsj-16000114
ER  -